[go: up one dir, main page]

EE04492B1 - Gestageense ja androgeense segatoimega mittesteroidsed (hetero)tsükliliselt asendatud atsüülaniliidid - Google Patents

Gestageense ja androgeense segatoimega mittesteroidsed (hetero)tsükliliselt asendatud atsüülaniliidid

Info

Publication number
EE04492B1
EE04492B1 EEP199900548A EEP9900548A EE04492B1 EE 04492 B1 EE04492 B1 EE 04492B1 EE P199900548 A EEP199900548 A EE P199900548A EE P9900548 A EEP9900548 A EE P9900548A EE 04492 B1 EE04492 B1 EE 04492B1
Authority
EE
Estonia
Prior art keywords
gestagenic
androgenic
steroidal
hetero
substituted acyl
Prior art date
Application number
EEP199900548A
Other languages
English (en)
Estonian (et)
Inventor
Lehmann Manfred
Sch�llkopf Klaus
Strehlke Peter
Heinrich Nikolaus
Fritzemeier Karl-Heinrich
Muhn Hans-Peter
Krattenmacher Rolf
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7831567&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE04492(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of EE9900548A publication Critical patent/EE9900548A/xx
Publication of EE04492B1 publication Critical patent/EE04492B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/22—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/02—1,2-Oxazines; Hydrogenated 1,2-oxazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/76—Benzo[c]pyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/72—Benzo[c]thiophenes; Hydrogenated benzo[c]thiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Furan Compounds (AREA)
  • Materials For Medical Uses (AREA)
EEP199900548A 1997-05-30 1998-06-02 Gestageense ja androgeense segatoimega mittesteroidsed (hetero)tsükliliselt asendatud atsüülaniliidid EE04492B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19723722A DE19723722A1 (de) 1997-05-30 1997-05-30 Nichtsteroidale Gestagene
PCT/EP1998/003242 WO1998054159A1 (fr) 1997-05-30 1998-06-02 Acylanilides non steroidiques heterocycliquement substitues a effet mixte gestagene et androgene

Publications (2)

Publication Number Publication Date
EE9900548A EE9900548A (et) 2000-06-15
EE04492B1 true EE04492B1 (et) 2005-06-15

Family

ID=7831567

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900548A EE04492B1 (et) 1997-05-30 1998-06-02 Gestageense ja androgeense segatoimega mittesteroidsed (hetero)tsükliliselt asendatud atsüülaniliidid

Country Status (30)

Country Link
EP (1) EP0986545B1 (fr)
JP (1) JP2002502385A (fr)
KR (1) KR100536870B1 (fr)
CN (1) CN100445272C (fr)
AR (1) AR011480A1 (fr)
AT (1) ATE286035T1 (fr)
AU (1) AU747083C (fr)
BG (1) BG64212B1 (fr)
BR (1) BR9809703A (fr)
CA (1) CA2305458C (fr)
CZ (1) CZ296377B6 (fr)
DE (2) DE19723722A1 (fr)
EA (1) EA004306B1 (fr)
EE (1) EE04492B1 (fr)
ES (1) ES2234121T3 (fr)
HR (1) HRP980289B1 (fr)
HU (1) HUP0002126A3 (fr)
ID (1) ID23499A (fr)
IL (2) IL133195A0 (fr)
IS (1) IS2498B (fr)
NO (1) NO325076B1 (fr)
NZ (1) NZ501359A (fr)
PL (1) PL197887B1 (fr)
PT (1) PT986545E (fr)
SK (1) SK284943B6 (fr)
TR (1) TR199902924T2 (fr)
TW (1) TW577882B (fr)
UA (1) UA64752C2 (fr)
WO (1) WO1998054159A1 (fr)
ZA (1) ZA984655B (fr)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19856475A1 (de) * 1998-11-27 2000-05-31 Schering Ag Nichtsteroidale Entzündungshemmer
DE10038639A1 (de) 2000-07-28 2002-02-21 Schering Ag Nichtsteroidale Entzündungshemmer
DE10346940B3 (de) * 2003-10-06 2005-06-16 Schering Ag Substituierte Pentanole, ihre Verwendung zur Herstellung von Arzneimitteln speziell Entzündungshemmer sowie diese enthaltende pharmazeutische Präparate
WO2002054064A2 (fr) * 2000-12-28 2002-07-11 Schering Ag Procede de criblage de ligands a specificite pour l'isoforme des recepteurs de progesterone et de ligands de recepteurs de progesterone a selectivite tissulaire
DE60309829T2 (de) * 2002-01-14 2007-09-13 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Glucocorticoidmimetika, verfahren zu ihrer herstellung, diese enthaltende pharmazeutische formulierungen und ihre verwendungen
HRP20040923A2 (en) * 2002-03-11 2004-12-31 Schering Ag 5-{2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino}-phtalide and related compounds with progesterone receptor modulating activity for use in fertility control and hormone replacement therapy
EP1344776A1 (fr) * 2002-03-11 2003-09-17 Schering Aktiengesellschaft Dérivés de la 5- 2-hydroxy-3-[1-(3-trifluorométhylphényl)-cyclopropyl]-propionylamino -phtalide et de la 6- 2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino -4-methyl-2,3-benzoxazin-1-one avec une activité modulante du recepteur de la progesterone pour l'utilisation dans la contraception , la therapie du remplacement hormonell et le traitement des troubles gynécologiques
KR101022977B1 (ko) 2002-03-26 2011-03-18 베링거 인겔하임 파마슈티칼즈, 인코포레이티드 글루코코르티코이드 모사체, 이의 제조방법, 약제학적조성물 및 이의 용도
JP2005521717A (ja) 2002-03-26 2005-07-21 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド グルココルチコイドミメチックス、その製造方法、その医薬組成物、及び使用
DE10215316C1 (de) * 2002-04-02 2003-12-18 Schering Ag Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
AU2003259747A1 (en) 2002-08-21 2004-03-11 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
CN1678306A (zh) 2002-08-29 2005-10-05 贝林格尔·英格海姆药物公司 在炎性、变应性和增生性疾病中用作糖皮质激素模拟物的3－(磺酰氨基乙基)－吲哚衍生物
CA2501867A1 (fr) * 2002-10-15 2004-04-29 James T. Dalton Modulateurs heterocycliques selectifs du recepteur des androgenes et procedes d'utilisation associes
DE10261874A1 (de) * 2002-12-20 2004-07-08 Schering Ag Nichtsteroidale Entzündungshemmer
MXPA05006872A (es) 2003-01-03 2005-08-16 Boehringer Ingelheim Pharma Derivados de 1-propanol y 1-propilamina y su uso como ligandos glucocorticoides.
US20040224992A1 (en) * 2003-02-27 2004-11-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
RS20050974A (sr) * 2003-07-01 2007-09-21 Schering Aktiengesellschaft, Heterociklično supstituisani pentanol-derivati,postupak za njihovo dobijanje i njihova primena kao supresora zapaljenja
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
UY28526A1 (es) 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
JP4468369B2 (ja) 2003-10-16 2010-05-26 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド ある種のトリフルオロメチル置換アルコールの立体選択的合成
US7795272B2 (en) 2004-03-13 2010-09-14 Boehringer Ingelheim Pharmaceutical, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
DE102004062182B4 (de) * 2004-12-20 2007-06-06 Bayer Schering Pharma Ag Transdermales Pflaster mit Progesteron A-Spezifische Liganden (PRASL) als Wirkstoff
ES2326907T3 (es) 2004-12-27 2009-10-21 Boehringer Ingelheim Pharmaceuticals Inc. Mimeticos de glucocorticoides, metodos para su preparacion, composiciones farmaceuticas y su uso.
ATE517908T1 (de) 2005-01-10 2011-08-15 Glaxo Group Ltd Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände
JPWO2006083030A1 (ja) * 2005-02-04 2008-06-26 味の素株式会社 脂肪酸の製造方法および脂肪酸の塩結晶
UY29439A1 (es) 2005-03-25 2006-10-02 Glaxo Group Ltd Nuevos compuestos
PE20100737A1 (es) 2005-03-25 2010-11-27 Glaxo Group Ltd Nuevos compuestos
DE102005017326A1 (de) * 2005-04-14 2007-03-29 Schering Ag Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
DE102005030293A1 (de) * 2005-06-24 2007-01-04 Schering Ag Verwendung von nichtsteroidale Progesteronrezeptor-Modulatoren
DE102005030294A1 (de) * 2005-06-24 2007-01-04 Schering Ag Nichtsteroidale Progesteronrezeptor-Modulatoren
US7408060B2 (en) 2005-06-24 2008-08-05 Schering Ag Nonsteroidal progesterone receptor modulators
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
AU2006324097B2 (en) * 2005-12-09 2011-08-25 F. Hoffmann-La Roche Ag Glucocorticoid receptor modulators as antiinflammatory agents
AR058109A1 (es) 2005-12-20 2008-01-23 Glaxo Group Ltd Acido 3 - (4 - {[4 -(4 -{[3 - (3, 3 - dimetil - 1 - piperidinil)propil]oxi}fenil) - 1 - piperidinil]carbonil} - 1 - naftalenil)propanoico como antagonistas de los receptotres de histamina h1/h3, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamie
BRPI0710240A2 (pt) 2006-04-20 2011-08-09 Glaxo Group Ltd composto, uso de um composto, método para o tratamento de um paciente humano ou animal com uma condição ou doença, composição farmacêutica, combinação, e, processo para a preparação de um composto
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
RU2009125614A (ru) 2006-12-06 2011-01-20 Бёрингер Ингельхайм Интернациональ Гмбх (De) Глюкокортикоидные миметики, способы их получения, фармацевтические композиции и их применения
UY30805A1 (es) * 2006-12-21 2008-07-31 Bayer Schering Pharma Ag Moduladores no esteroides de receptores de progesterona
UY30815A1 (es) * 2006-12-21 2008-07-31 Bayer Schering Pharma Ag Moduladores no esteroidales del receptor de progesterona
DE102007023614A1 (de) 2007-05-21 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
DE102007049630A1 (de) 2007-10-11 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
JP5090773B2 (ja) 2006-12-26 2012-12-05 国立大学法人東京工業大学 光学活性含フッ素カルボニル−エン生成物の製造方法
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
DE102007032800A1 (de) 2007-07-10 2009-01-15 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
DE102007058747A1 (de) 2007-12-05 2009-06-10 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
EP2070909A1 (fr) * 2007-12-15 2009-06-17 Bayer Schering Pharma AG Modulateurs de récepteur de progestérone non stéroïdiens
EP2285803A4 (fr) 2008-05-23 2011-10-05 Amira Pharmaceuticals Inc Inhibiteur de la protéine d activation de 5-lipoxygénase
US8163743B2 (en) 2008-06-05 2012-04-24 GlaxoGroupLimited 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases
WO2009147190A1 (fr) 2008-06-05 2009-12-10 Glaxo Group Limited Nouveaux composés
BRPI0915680A2 (pt) 2008-06-06 2019-09-24 Boehringer Ingelheim Int miméticos de glicocorticoide, métodos de prepará-los, composições farmacêuticas, e usos dos mesmos
WO2010094643A1 (fr) 2009-02-17 2010-08-26 Glaxo Group Limited Dérivés de quinoline et applications associées dans la rhinite et l'urticaire
US8524751B2 (en) 2009-03-09 2013-09-03 GlaxoSmithKline Intellecutual Property Development 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
JP2012520845A (ja) 2009-03-17 2012-09-10 グラクソ グループ リミテッド Ｉｔｋ阻害剤として使用されるピリミジン誘導体
JP2012520683A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いた結合組織増殖因子（ＣＴＧＦ）遺伝子発現のＲＮＡ干渉媒介性阻害
EP2408915A2 (fr) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. Inhibition induite par arn interférence d'une expression génique (gata3) d'une protéine de liaison gata au moyen d'un acide nucléique interférent court
AU2010226604A1 (en) 2009-03-19 2011-10-13 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of BTB and CNC homology 1, basic leucine zipper transcription factor 1 (Bach 1) gene expression using short interfering nucleic acid (siNA) sequence listing
WO2010107958A1 (fr) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. INHIBITION INDUITE PAR ARN INTERFÉRENCE DE L'EXPRESSION DU GÈNE TRANSDUCTEUR DE SIGNAL ET ACTIVITATEUR DE TRANSCRIPTION 6 (STAT6) AU MOYEN D'UN ACIDE NUCLÉIQUE INTERFÉRENT COURT (ANsi)
WO2010111490A2 (fr) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. Inhibition à médiation par l'interférence arn de l'expression du gène de la lymphopoïétine stromale thymique (tslp) faisant appel à de courts acides nucléiques interférents (ansi)
WO2010111468A2 (fr) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. INHIBITION PAR INTERFÉRENCE ARN DE L'EXPRESSION DU GÈNE DE LA CHAÎNE BÊTA DU FACTEUR DE CROISSANCE DES NERFS (NGFß) AU MOYEN D'UN ACIDE NUCLÉIQUE INTERFÉRENT COURT (ANSI)
EP2411517A2 (fr) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. Inhibition à médiation par l'interférence arn de l'expression du gène de la molécule d'adhésion intercellulaire 1 (icam-1) faisant appel à de courts acides nucléiques interférents (ansi)
EP2411019A2 (fr) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. Inhibition par interférence arn de l'expression du gène du signal transducteur et activateur de la transcription 1 (stat1) au moyen d'un acide nucléique interférent court (ansi)
WO2010111464A1 (fr) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. Inhibition par interférence arn de l'expression du gène kinase 1 de régulation du signal d'apoptose (ask1) au moyen d'un acide nucléique interférent court (ansi)
AR076373A1 (es) 2009-04-24 2011-06-08 Glaxo Group Ltd N-pirazolil carboxamidas como inhibidores de canales de calcio
JP2012524754A (ja) 2009-04-24 2012-10-18 グラクソ グループ リミテッド Ｃｒａｃチャネル阻害剤としてのピラゾールおよびトリアゾ−ルカルボキサミド
ES2876933T3 (es) 2009-04-30 2021-11-15 Glaxo Group Ltd Indazoles sustituidos con oxazol como inhibidores de PI3-cinasas
EP2507226A1 (fr) 2009-12-03 2012-10-10 Glaxo Group Limited Nouveaux composés
JP2013512879A (ja) 2009-12-03 2013-04-18 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤としてのベンズピラゾール誘導体
JP2013512880A (ja) 2009-12-03 2013-04-18 グラクソ グループ リミテッド Ｐｉ３−キナーゼ阻害剤としてのインダゾール誘導体
EP3020393B1 (fr) 2009-12-16 2020-10-07 3M Innovative Properties Company Formulations et procédés de commande de distribution granulométrique mdi
WO2011110575A1 (fr) 2010-03-11 2011-09-15 Glaxo Group Limited Dérivés de 2-[2-(benzo- ou pyrido-)thiazolylamino]-6- aminopyridine, utiles dans le traitement de maladies respiratoires, allergiques ou inflammatoires
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
US9326987B2 (en) 2010-09-08 2016-05-03 Glaxo Group Limited Indazole derivatives for use in the treatment of influenza virus infection
SI2614058T1 (sl) 2010-09-08 2015-10-30 Glaxosmithkline Intellectual Property Development Limited Polimorfi in soli N-(5-(4-(5-(((2R,6S)-2,6-dimetil-4-morfolinil)metil)-1,3-oksazol-2-il)- 1H-indazol-6-il)-2-(metiloksi)-3-piridinil)metansulfonamida
WO2012035055A1 (fr) 2010-09-17 2012-03-22 Glaxo Group Limited Nouveaux composés
ES2532213T3 (es) 2010-10-21 2015-03-25 Glaxo Group Limited Compuestos de pirazol que actúan contra afecciones alérgicas, inmunitarias e inflamatorias
JP2013544794A (ja) 2010-10-21 2013-12-19 グラクソ グループ リミテッド アレルギー性障害、炎症性障害及び免疫障害に作用するピラゾール化合物
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
WO2012123312A1 (fr) 2011-03-11 2012-09-20 Glaxo Group Limited Dérivés pyrido[3,4-b]pyrazine en tant qu'inhibiteurs de syk
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
AU2014321420B2 (en) 2013-09-22 2017-06-15 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
AU2014336250A1 (en) 2013-10-17 2016-04-14 Glaxosmithkline Intellectual Property Development Limited PI3K inhibitor for treatment of respiratory disease
KR20160062178A (ko) 2013-10-17 2016-06-01 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 호흡기 질병의 치료를 위한 ｐｉ３ｋ 억제제
US9403801B2 (en) 2014-03-28 2016-08-02 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
PE20170185A1 (es) 2014-05-12 2017-04-01 Glaxosmithkline Intellectual Property (No 2) Ltd Composiciones farmaceuticas para tratar enfermedades infecciosas
US9938257B2 (en) 2015-09-11 2018-04-10 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
WO2018029126A1 (fr) 2016-08-08 2018-02-15 Glaxosmithkline Intellectual Property Development Limited Composés chimiques
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
EP3569228A1 (fr) * 2018-05-17 2019-11-20 Association pour la recherche à l'IGBMC (ARI) Modulateurs agonistes de récepteurs de glucocorticoïdes sélectifs (segrams) non stéroïdiens et leurs utilisations
JP7254076B2 (ja) 2017-11-19 2023-04-07 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 置換ヘテロアリール化合物及び使用方法
KR102737185B1 (ko) 2018-01-20 2024-12-05 선샤인 레이크 파르마 컴퍼니 리미티드 치환된 아미노피리미딘 화합물 및 이의 사용 방법
CA3173172A1 (fr) 2020-03-26 2021-09-30 Christopher D. Kane Inhibiteurs de cathepsine pour la prevention ou le traitement d'infections virales
JP7797421B2 (ja) * 2020-06-12 2026-01-13 上海済▲ユウ▼医薬科技股▲フン▼有限公司 フタラジノン化合物、並びにその調製方法及びその医薬用途
CN114605308B (zh) * 2022-03-18 2023-12-19 阜新孚隆宝医药科技有限公司 一种帕罗韦德的氮杂双环医药中间体的制备方法及中间体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4191775A (en) * 1977-12-15 1980-03-04 Imperial Chemical Industries Limited Amide derivatives
NZ197008A (en) * 1980-05-22 1984-10-19 Ici Ltd Acylanilide derivatives and pharmaceutical compositions
JPS5789048A (en) * 1980-11-20 1982-06-03 Nat Jutaku Kenzai Independent pilar with cover
CA1261835A (fr) * 1984-08-20 1989-09-26 Masaaki Toda Benz(thio) amides fusionnes
GB8617653D0 (en) * 1986-07-18 1986-08-28 Ici Plc Amide derivatives
GB8617652D0 (en) * 1986-07-18 1986-08-28 Ici Plc Acylanilide derivatives
NZ254534A (en) * 1992-07-01 1997-12-19 Ortho Pharma Corp 1,4,5,6-tetrahydro-pyridazine derivatives, preparation and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
BG64212B1 (bg) 2004-05-31
NZ501359A (en) 2001-11-30
ES2234121T3 (es) 2005-06-16
EA199900989A1 (ru) 2000-08-28
IS2498B (is) 2009-02-15
IS5241A (is) 1999-11-09
CN1258286A (zh) 2000-06-28
EP0986545B1 (fr) 2004-12-29
KR20010013123A (ko) 2001-02-26
NO325076B1 (no) 2008-01-28
WO1998054159A1 (fr) 1998-12-03
UA64752C2 (uk) 2004-03-15
EE9900548A (et) 2000-06-15
AU8021198A (en) 1998-12-30
IL133195A0 (en) 2001-03-19
IL133195A (en) 2007-07-24
HUP0002126A2 (hu) 2001-06-28
HUP0002126A3 (en) 2002-12-28
KR100536870B1 (ko) 2005-12-16
SK160999A3 (en) 2000-07-11
SK284943B6 (sk) 2006-02-02
ZA984655B (en) 1999-03-16
EA004306B1 (ru) 2004-02-26
TR199902924T2 (xx) 2000-02-21
HRP980289A2 (en) 1999-02-28
DE59812452D1 (de) 2005-02-03
PT986545E (pt) 2005-04-29
CN100445272C (zh) 2008-12-24
PL197887B1 (pl) 2008-05-30
BG103903A (en) 2000-04-28
ATE286035T1 (de) 2005-01-15
AU747083B2 (en) 2002-05-09
CZ296377B6 (cs) 2006-03-15
HRP980289B1 (en) 2005-08-31
AU747083C (en) 2004-01-29
NO995845L (no) 2000-01-27
TW577882B (en) 2004-03-01
BR9809703A (pt) 2000-07-11
CA2305458C (fr) 2007-05-01
PL337088A1 (en) 2000-07-31
ID23499A (id) 2000-04-27
CZ425799A3 (cs) 2000-04-12
CA2305458A1 (fr) 1998-12-03
EP0986545A1 (fr) 2000-03-22
DE19723722A1 (de) 1998-12-10
JP2002502385A (ja) 2002-01-22
NO995845D0 (no) 1999-11-29
AR011480A1 (es) 2000-08-16

Similar Documents

Publication Publication Date Title
EE9900548A (et) Gestageense ja androgeense segatoimega mittesteroidsed (hetero) tsükliliselt asendatud atsüülaniliidid
FI990466A0 (fi) Aktivaattorit ja laite
FI963126L (fi) Stanoliseos ja sen käyttö
PT1011621E (pt) Metodos e composicoes para branqueamento dos dentes
IS1788B (is) Andestrogen benzothiophenyl efnasambönd
KR100524623B1 (ko) 혼합 장치
PT910462E (pt) Dispositivo misturador e distribuidor
ID20993A (id) Campuran semen dan komposisi semen
DE69820278D1 (de) Mischverfahren und mischvorrichtung
EE03409B1 (et) Kõrge efektiivsusega segusti ja selle valmistamise meetod
FI973866L (fi) Menetelmä ja laite maa-ainesten sekoittamiseksi
EE03582B1 (et) Meetod ja seade alalispinge muundamiseks
IS5331A (is) Ný lyfjablanda
PT1140110E (pt) Clatratos de desidroepiandrosterona e correspondentes composicoes farmaceuticas
FI960994L (fi) Erotuslaite ja siinä olevia komponentteja
DE59803259D1 (de) Mischvorrichtung
FI955253A7 (fi) Sekoituslaite
FI982195A7 (fi) Laite tasokompostin kääntämiseksi ja/tai sekoittamiseksi
EP0754701A4 (fr) Nouveau compose de progesterone et son utilisation
EE200000352A (et) Elektrilist skeemi sisaldava seadmega seotud konstruktsioonid ja meetod
DE69820650D1 (de) Verbesserter alginatmischer
DK0986545T3 (da) Ikke-steroide, (hetero) cyclisk substituerede acyanilider med blandet gestagen og androgen aktivitet
ATE277070T1 (de) Sulfatierung von östrogen-mischungen
FI990281L (fi) Liitos erityisesti rakenne-elementtejä varten ja rakenne-elementti
FI3844U1 (fi) Kiinnitysväline toisiaan vastaan kulmassa olevien sekä samansuuntaisten osien liittämiseksi yhteen

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

MM4A Lapsed by not paying the annual fees

Effective date: 20090602